Zuranolone in postpartum depression: dose and care

A 31-year-old woman had her first child six weeks ago, by vaginal delivery, without complications. Since the second week she sleeps badly even when the baby sleeps, cries almost every day, has lost interest in the things she used to enjoy and feels she is not a good mother. At the postpartum visit, the Edinburgh scale gave a high score. She is breastfeeding and intends to continue. In the interview, the doctor asks directly about thoughts of death; she reports tiredness and hopelessness, without intention or plan, and has her partner and her mother at home. She has never used an antidepressant and would go back to driving the following month. She asks whether there is a treatment that works fast. The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. It covers zuranolone, a 14-day oral medicine approved for postpartum depression in adults. The text explains the indication, the dose, the warnings about drowsiness and driving, breastfeeding, contraception, what the studies showed and where the limits of the evidence are. It does not replace your institution's protocol or the local package insert, and it does not replace the risk assessment made by a professional. If you play the case of the day on NEXO, you will recognize the challenge: deciding with clues that arrive in sequence.

Key points

• Zuranolone (brand name Zurzuvae) is indicated in the United States and the European Union for postpartum depression in adults.
• The American dose is 50 mg orally once a day, at night, with food that contains fat, for 14 days.
• The package insert carries a boxed warning: the person must not drive until at least 12 hours after each dose, throughout the whole treatment.
• In the studies, the improvement on the Hamilton scale on day 15 was about 4 points greater than with placebo.
• Drowsiness, dizziness, diarrhea, tiredness and urinary infection were the most common effects.
• The regulatory dates in this text were checked at the FDA and the EMA on October 24, 2026.

Why this is a reasoning scenario

Depression in the perinatal period is common. A meta-analysis notes that studies in high-income countries estimate a prevalence of 11 percent during pregnancy and 13 percent postpartum (Smythe et al., 2022). A review on risk and access to treatment estimates that almost 1 in every 7 women has symptoms compatible with major depression in this period (Gopalan et al., 2022). The same review cites data from United States maternal mortality review committees according to which 68 percent of pregnancy-related deaths would be preventable, and most of them are linked to mental health conditions (Gopalan et al., 2022). Another review notes that suicide, which can result from psychosis or untreated depression, is a common cause of maternal death worldwide (Lim, 2021).

The scenario is good for training because it brings together several decisions: confirming the diagnosis, assessing the risk, choosing between psychotherapy, an antidepressant and a new medicine, and planning the mother's practical life during treatment. The post on signs, symptoms and history helps organize the interview, and the post on clinical decision-making reminds us that each option trades one risk for another.

What the scene teaches

The scene trains six habits. The first is to use a validated scale without letting it replace the interview. The second is to ask directly about thoughts of death and record the answer. The third is to investigate other causes, such as thyroid disease and anemia. The fourth is to know the dose, the interactions and the adjustments of zuranolone. The fifth is to plan for drowsiness, driving, breastfeeding and contraception. The sixth is to arrange the reassessment after the 14 days.

What is not at stake

The text does not discuss postpartum psychosis, bipolar disorder, depression during pregnancy or treatment of adolescents. It also does not compare prices or access. Postpartum psychosis and any sign of immediate risk call for urgent assessment at a health service, not a 14-day outpatient treatment. The post about diagnostic uncertainty helps decide when the clue changes the course.

Recognizing postpartum depression

Screening

A review recalls that the National Institute for Health and Care Excellence of the United Kingdom, NICE, and the American College of Obstetricians and Gynecologists, ACOG, recommend screening for depression and anxiety at least once in the perinatal period with a standardized and validated instrument (Lim, 2021). A positive screen should lead to referral for mental health assessment (Lim, 2021). The Edinburgh scale was created in 1987 to help primary care professionals detect postpartum depression and is widely used during pregnancy and the postpartum period (Oliveira and colleagues, 2022). A Brazilian study cites authors who suggest a cutoff of 11 to 12, with sensitivity of 72 percent and specificity of 88 percent, and used a score of 12 or more as indicating depression (Oliveira and colleagues, 2022).

The interview

The scale points, but does not diagnose. The interview confirms the timing of symptoms, their intensity, the impact on caring for the baby and on daily life, the history of depression or of episodes of euphoria and substance use. The review on risk and access recalls that trauma should be considered an important risk factor for perinatal depression and argues for universal trauma screening (Gopalan and colleagues, 2022). It also cites a study of 138 countries that found younger maternal age, first pregnancy and twins as risk factors for depressive symptoms in the postpartum period (Gopalan and colleagues, 2022).

Assessing risk

Asking directly about thoughts of death is part of the assessment. If there is intent, a plan, psychotic symptoms or an inability to care for oneself or the baby, the approach changes to urgent assessment at a health service, with the family informed. In the scene, the woman reports hopelessness, with no intent or plan, and has support at home. Even so, the US label asks that patients and families be advised to report immediately the emergence of suicidal thoughts or worsening depression (US label of Zurzuvae, 4/2026).

Barriers to treatment

A review on perinatal depression lists barriers linked to the patient, to professionals and to systems: stigma, cultural factors, fear of adverse effects of antidepressants, limited access to mental health care, little training of perinatal professionals and little coordination between teams (Dagher and colleagues, 2021). The same review cites research that associates paid leave after childbirth with better perinatal mental health (Dagher and colleagues, 2021). In the scene, the treatment has to fit into a routine with a six-week-old baby.

Breastfeeding

A meta-analysis found an association between postpartum depression and lower breastfeeding self-efficacy (Ahmadinezhad and colleagues, 2024). The authors recall that increasing breastfeeding self-efficacy can improve the mother's satisfaction, communication between mother and baby and the child's health (Ahmadinezhad and colleagues, 2024). That is why the wish to continue breastfeeding enters the choice of treatment.

How zuranolone works

The EMA summarizes that zuranolone increases the activity of the neurotransmitter GABA, which takes part in mood regulation (EMA, Zurzuvae page). The ROBIN study article recalls that levels of the neurosteroid allopregnanolone change greatly in the perinatal period and that these changes can affect GABA signaling and the emergence of postpartum depression (Deligiannidis and colleagues, 2021).

A relative of brexanolone

A preclinical study recalls that brexanolone is an intravenous formulation of allopregnanolone that showed efficacy in postpartum depression (Althaus et al., 2020). The authors explain that synthetic analogs of this class were developed to maintain the action on the GABA A receptor and improve oral absorption (Althaus et al., 2020). Zuranolone is one of these positive allosteric modulators, with oral bioavailability of 62 percent in mice (Althaus et al., 2020).

Synaptic and extrasynaptic receptors

The same study explains that GABA A receptors with the gamma subunit predominate at synapses, while those with the delta subunit are mostly outside them (Althaus et al., 2020). Zuranolone acts on both types (Althaus et al., 2020). This broad action helps explain why drowsiness and dizziness appear in the studies.

What this changes in practice

Antidepressants used for decades take weeks to act and are taken for months. Zuranolone is taken for 14 days. The US label says it can be used alone or with an oral antidepressant, and that safety and efficacy beyond 14 days have not been established (US Zurzuvae label, 4/2026). This does not remove the need for follow-up: depression can return, and the plan after day 14 needs to be agreed before day 1.

Regulatory status: FDA and EMA

United States. The FDA approved Zurzuvae on August 4, 2023, under NDA 217369 (Drugs@FDA, NDA 217369). Drugs@FDA lists label changes on July 31, 2024, and on April 20, 2026 (Drugs@FDA, NDA 217369). The label consulted was revised in April 2026 (US Zurzuvae label, 4/2026). The indication is the treatment of postpartum depression in adults (US Zurzuvae label, 4/2026). Zuranolone is a Schedule IV controlled substance in the United States (US Zurzuvae label, 4/2026).

European Union. The EMA human medicines committee gave a positive opinion on July 24, 2025, and Zurzuvae received a marketing authorization valid throughout the European Union on September 17, 2025 (EMA, Zurzuvae page). The page was consulted on October 24, 2026, and had last been updated on October 31, 2025 (EMA, Zurzuvae page). The EMA describes use in capsules, once a day at night, for 14 days, alone or with another antidepressant (EMA, Zurzuvae page). The EMA also says Zurzuvae should not be used during pregnancy (EMA, Zurzuvae page).

Other countries. This text does not describe registration in other countries. Availability depends on the local agency.

What the studies showed

The ROBIN study

The phase 3 ROBIN study randomized 153 outpatient women with postpartum depression to zuranolone 30 mg or placebo for 2 weeks (Deligiannidis et al., 2021). The difference on the Hamilton scale favored zuranolone at every point measured, from day 3 to day 45, four weeks after the end of treatment (Deligiannidis et al., 2021). On day 3, the difference was 2.7 points, and on day 45, 4.1 points (Deligiannidis et al., 2021). Also on day 3, remission occurred in 19 percent with zuranolone and in 5 percent with placebo (Deligiannidis et al., 2021). The US label describes this study as study 2, done with another formulation, equivalent to about 40 mg of the current product: the drop on day 15 was 17.8 points with the drug and 13.6 with placebo, a difference of 4.2 (US Zurzuvae label, 4/2026).

The SKYLARK study

The US label describes as study 1 the trial with the 50 mg dose, with 98 patients on the drug and 97 on placebo (US Zurzuvae label, 4/2026). The drop on the Hamilton scale on day 15 was 15.6 points with the drug and 11.6 with placebo, a difference of 4.0 points (US Zurzuvae label, 4/2026). The EMA summarizes the same main study, with 200 women with severe postpartum depression, and describes a drop of about 10 points on day 3 with the drug, against about 6 with placebo (EMA, Zurzuvae page). In study 1, the mean age was 30 years, and 15 percent were on a stable oral antidepressant at baseline (US Zurzuvae label, 4/2026).

The meta-analysis

A systematic review with meta-analysis of the two randomized studies found a higher response rate on the clinical global impression scale with zuranolone, with an odds ratio of 2.31 (Oliveira and colleagues, 2024). Remission was more frequent with the drug on days 3, 15 and 45, with odds ratios of 2.59, 2.23 and 2.20 (Oliveira and colleagues, 2024). Because it brings together only two studies, the meta-analysis does not change the size of the evidence, but it shows that the results were similar.

The table summarizes the two studies.

Study	Dose	Participants	Drop on day 15 with the drug	Drop on day 15 with placebo	Difference	Source
Study 1 (SKYLARK)	50 mg	98 versus 97	15.6	11.6	4.0	(US label for Zurzuvae, 4/2026)
Study 2 (ROBIN)	30 mg of another formulation, about 40 mg of the current product	153 randomized	17.8	13.6	4.2	(Deligiannidis and colleagues, 2021) (US label for Zurzuvae, 4/2026)

Adverse effects

The label lists drowsiness, dizziness, diarrhea, fatigue, cold and urinary infection as the most common adverse reactions (US label for Zurzuvae, 4/2026). In study 1, drowsiness occurred in 36 percent with 50 mg and in 6 percent with placebo (US label for Zurzuvae, 4/2026). In study 2, it occurred in 19 percent with the drug and in 11 percent with placebo (US label for Zurzuvae, 4/2026). In each study, some patients had a confusional state; one of them was serious and came with drowsiness, dizziness and gait disturbance (US label for Zurzuvae, 4/2026). In ROBIN, one patient had confusion with sedation on day 3, resolved in 7 hours (Deligiannidis and colleagues, 2021).

How to read these numbers

The studies compared zuranolone with placebo, and not with sertraline, psychotherapy or brexanolone. Follow-up was short, up to day 45. The difference of about 4 points seems small on a scale that goes beyond 50 points, but it came early, already on day 3. For the woman in the scene, the honest promise is a faster response in some patients, with drowsiness as the price, and not a cure in two weeks. The post about diagnostic pause reminds us to stop before attributing every symptom to depression.

From indication to follow-up

Before prescribing, five questions change the approach: is there an immediate risk, are there psychotic or euphoric symptoms, how are the liver and kidneys, which medicines does she use and who will help on the nights of treatment.

The options

A 2025 European guideline strongly recommends cognitive behavioral therapy for depressive symptoms during pregnancy and postpartum (Radoš and colleagues, 2025). Interpersonal therapy and third-wave therapies received a weak recommendation (Radoš and colleagues, 2025). The guideline strongly recommends treating postpartum depression with an antidepressant after weighing the risks and benefits for the woman and the breastfed child (Radoš and colleagues, 2025). It also recommends brexanolone for moderate to severe postpartum depression, if available and accepted by the woman (Radoš and colleagues, 2025). The guideline makes no recommendation about zuranolone.

The dose

The US label calls for 50 mg orally once a day, at night, for 14 days, with food that contains fat, for example a meal of 400 to 1000 calories with 25 to 50 percent fat (US label for Zurzuvae, 4/2026). If there are central nervous system depressant effects, the dose can be reduced to 40 mg (US label for Zurzuvae, 4/2026). With strong CYP3A4 inhibitors, the dose is 30 mg; with CYP3A4 inducers, use should be avoided (US label for Zurzuvae, 4/2026). In severe hepatic impairment, Child-Pugh class C, and in moderate or severe renal impairment, with filtration below 60 mL/min/1.73 m², the dose is 30 mg (US label for Zurzuvae, 4/2026). If a dose is missed, the next one is taken at the usual time the following night, without taking extra capsules (US label for Zurzuvae, 4/2026).

Warnings

The boxed warning concerns driving: in two simulation studies, the driving ability of healthy adults worsened in a dose-dependent way (US label for Zurzuvae, 4/2026). A person should not drive or do hazardous activities until at least 12 hours after each dose during the 14 days, and may not notice their own drowsiness (US label for Zurzuvae, 4/2026). Use with alcohol, opioids or other central nervous system depressants increases the risk of sedation (US label for Zurzuvae, 4/2026). The label does not list contraindications (US label for Zurzuvae, 4/2026).

Pregnancy, contraception and breastfeeding

Based on animal studies, zuranolone may cause fetal harm (US label for Zurzuvae, 4/2026). The label calls for effective contraception during treatment and for 1 week after the last dose (US label for Zurzuvae, 4/2026). In a lactation study with 14 healthy women who took 30 mg for 5 days, zuranolone appeared at low levels in milk, with a relative infant dose below 1 percent (US label for Zurzuvae, 4/2026). There are no data on effects in the breastfed infant, and data on milk production are limited (US label for Zurzuvae, 4/2026). The label calls for weighing the benefits of breastfeeding, the mother's clinical need and the possible effects on the infant (US label for Zurzuvae, 4/2026).

• Take 50 mg at night, with food that contains fat, for 14 days.
• Reduce to 40 mg if central nervous system depressant effects occur.
• Use 30 mg with a strong CYP3A4 inhibitor, in severe hepatic impairment and in moderate or severe renal impairment.
• Do not drive until at least 12 hours after each dose, throughout the whole treatment.
• Use effective contraception during treatment and for 1 week after.
• Report worsening depression or suicidal thoughts immediately.

Source of the list: (US label for Zurzuvae, 4/2026).

Applying it to the patient

The woman in the scene has no immediate risk, no psychotic symptoms and no history of euphoria. The team orders a blood count and thyroid function, reviews her medicines and confirms that she does not use CYP3A4 inhibitors or inducers. If zuranolone is chosen, the conversation covers the nighttime dose with a meal, drowsiness, driving, alcohol and contraception (US label for Zurzuvae, 4/2026). She will not drive during the 14 days, and her partner takes over the nights and transport. The decision about breastfeeding is hers, with the label information about milk (US label for Zurzuvae, 4/2026). In parallel, the team offers psychotherapy (Radoš and colleagues, 2025). The post on differential diagnosis helps to remember clinical causes of fatigue and low mood in the postpartum period.

Follow-up

The plan includes contact in the first days, an appointment near day 15, a repeat application of the scale and a joint decision about what to do if symptoms return. The family knows that worsening depression or thoughts of death call for immediate contact with the team or urgent assessment at a health service (US label for Zurzuvae, 4/2026). The post on interprofessional clinical reasoning shows how obstetrics, psychiatry, nursing, pediatrics and pharmacy build this plan together.

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by searching for the ICD-10 code. Postpartum depression is a good exercise because one direct question, one medicine in use or the family routine changes the management. The post on case-based learning explains why this format fixes knowledge.

Three exercises with cases

Change the kidney. Say what dose to use if the glomerular filtration rate were 45 mL/min/1.73 m².

Change the medicine in use. Say what to do if she took a CYP3A4 inducer for epilepsy.

Change the interview. Say how the management changes if she reported hearing voices or ideas that the baby is in danger.

The post on simulation of care helps train the direct question about thoughts of death and the conversation about driving and breastfeeding.

The limits on using the game are described on the Economy page of NEXO. If you research the teaching of clinical reasoning, the page for Researcher explains how to get in touch. Professionals who write or review cases find information on Curator and on Creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

How long does treatment last?

Fourteen days, one dose per night (US Zurzuvae label, 4/2026).

Can it be used together with an antidepressant?

Yes. The label says it can be used alone or together with an oral antidepressant (US Zurzuvae label, 4/2026).

Can I drive during treatment?

Not until at least 12 hours after each dose, throughout the 14 days (US Zurzuvae label, 4/2026).

Can I breastfeed?

The drug appears at low levels in milk, and there are no data on effects on the baby. The decision weighs the benefits of breastfeeding and the mother's need (US Zurzuvae label, 4/2026).

Is it approved in Europe?

Yes. Zurzuvae received authorization in the European Union on September 17, 2025 (EMA, Zurzuvae page).

Final checklist

• I confirmed the diagnosis with an interview, in addition to the scale.
• I asked directly about thoughts of death and recorded the answer.
• I ruled out psychotic symptoms, euphoria and clinical causes.
• I reviewed CYP3A4 inhibitors and inducers, liver and kidneys.
• I explained the dose at night with food that contains fat.
• I agreed that the patient would not drive until 12 hours after each dose.
• I talked about contraception and breastfeeding.
• I scheduled the reassessment near day 15 and the plan if symptoms return.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Ahmadinezhad GS, Karimi FZ, Abdollahi M, et al. Association between postpartum depression and breastfeeding self-efficacy in mothers: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024. PMID 38609849.
2. Althaus AL, Ackley MA, Belfort GM, et al. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology. 2020. PMID 32976892.
3. Biogen. ZURZUVAE® (zuranolone) capsules, for oral use, CIV. Prescribing Information. Revised 4/2026. Accessed 10/24/2026. Official source.
4. Dagher RK, Bruckheim HE, Colpe LJ, et al. Perinatal Depression: Challenges and Opportunities. J Womens Health (Larchmt). 2021. PMID 33156730.
5. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2021. PMID 34190962.
6. European Medicines Agency. Zurzuvae | European Medicines Agency (EMA). Accessed 10/24/2026. Official source.
7. Gopalan P, Spada ML, Shenai N, et al. Postpartum Depression-Identifying Risk and Access to Intervention. Curr Psychiatry Rep. 2022. PMID 36422834.
8. Lim G. Perinatal depression. Curr Opin Anaesthesiol. 2021. PMID 33935170.
9. Oliveira JA, Eskandar K, Freitas MAA, et al. Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies. Rev Bras Ginecol Obstet. 2024. PMID 39669307.
10. Oliveira TA, Luzetti GGCM, Rosalém MMA, et al. Screening of Perinatal Depression Using the Edinburgh Postpartum Depression Scale. Rev Bras Ginecol Obstet. 2022. PMID 35253138.
11. Radoš SN, Ganho-Ávila A, Rodriguez-Muñoz MF, et al. Evidence-based clinical practice guidelines for prevention, screening and treatment of peripartum depression. Br J Psychiatry. 2025. PMID 40566968.
12. Smythe KL, Petersen I, Schartau P. Prevalence of Perinatal Depression and Anxiety in Both Parents: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID 35749112.
13. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. NDA 217369, Zurzuvae. Accessed 10/24/2026. Official source.